Eli Lilly Licenses SpeechDx Dataset for Alzheimer's Research
Eli Lilly and Company has entered a collaboration with the Alzheimer's Drug Discovery Foundation to license the SpeechDx dataset for use in Alzheimer's disease research.
Stocks · News reference
Eli Lilly Says Retatrutide Delivers More Than Double Ozempic’s Weight Loss in Late-Stage Diabetes Trial
Lilly’s retatrutide delivered more than double Ozempic’s weight loss in head-to-head diabetes trial
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Global Dermatological Therapeutics Market to Reach USD 97 Billion by 2034 | DelveInsight
The global dermatological therapeutics market is projected to grow from USD 43 billion in 2025 to USD 97 billion by 2034, with a CAGR of approximately 10%. Growth is driven by rising prevalence of chronic skin disorders, adoption of biologics and JAK inhibitors, increased healthcare spending, and growing awareness of skin health. North America leads the market with 46% share, while Asia-Pacific is expected to register the fastest growth.
Eli Lilly Announces Positive Phase 3 Results for Retatrutide in Type 2 Diabetes
Eli Lilly reported positive topline results from the TRANSCEND-T2D-2 Phase 3 trial, demonstrating that its investigational triple agonist retatrutide achieved superior A1C reduction and weight loss compared to Ozempic in adults with type 2 diabetes.